A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Clinical trial NCT05900973 · UNKNOWN
Trial details
- NCT number
- NCT05900973
- Sponsor
- D'Or Institute for Research and Education
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-20
- Primary completion
- 2025-05-17
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.